Drug targets for Cancer: IL-13

Drug Targets for Cancer: IL-13 and Cancer

The Reed–Sternberg (RS) cells of classical Hodgkin lymphoma produce several cytokines, which are thought to account for the unique clinical and pathologic features of this disease. It was previously identified interleukin (IL)-13 expression as a common feature of classical Hodgkin lymphoma and have studied the potential role of this cytokine as an autocrine growth factor for RS cells. IL-13 and the IL-13-specific receptor chain (IL-13Ra1) are frequently expressed in classical Hodgkin lymphoma-derived cell lines and in RS cells from biopsies of classical Hodgkin lymphoma tissues. In contrast, IL-13 expression in non-Hodgkin lymphoma (NHL) is uncommon. Neutralization of IL-13 in cultures of classical Hodgkin lymphoma-derived cell lines HDLM-2 and L-1236 leads to a dosedependent inhibition of proliferation, and is associated with increased apoptosis in L-1236 cells. IL-13 neutralization also decreased activation of signal transducer and activator of transcription (STAT)6, an important mediator of IL-13 function. Moreover, STAT6 is often activated in RS cells from primary tumor samples, implying that IL-13 signaling is occurring in these cells in vivo.

Drug Targets for Cancer: IL-13 related Products

Drug targets for cancer: IL-13 research reagents

Other vital drug targets for cancer likeIL-13:

Drug Targets for Cancer: IL-13 Related Reference

Skinnider B F, et al. The role of interleukin 13 in classical Hodgkin lymphoma[J]. Leukemia & lymphoma, 2002, 43(6): 1203-1210.

Drug Targets for Cancer: IL-13 Related Information

Drug Targets for Cancer